Literature DB >> 15014525

Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis.

M A Elliott, A Pardanani, C Y Li, A Tefferi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15014525     DOI： 10.1038/sj.leu.2403329

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  3 in total

1.  The role of Lin28b in myeloid and mast cell differentiation and mast cell malignancy.

Authors:  L D Wang; T N Rao; R G Rowe; P T Nguyen; J L Sullivan; D S Pearson; S Doulatov; L Wu; R C Lindsley; H Zhu; D J DeAngelo; G Q Daley; A J Wagers
Journal:  Leukemia       Date:  2015-02-06       Impact factor: 11.528

Review 2.  Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.

Authors:  Ayalew Tefferi; Animesh Pardanani
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

3.  Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature.

Authors:  Iván Alvarez-Twose; Almudena Matito; José Mário Morgado; Laura Sánchez-Muñoz; María Jara-Acevedo; Andrés García-Montero; Andrea Mayado; Carolina Caldas; Cristina Teodósio; Javier Ignacio Muñoz-González; Manuela Mollejo; Luis Escribano; Alberto Orfao
Journal:  Oncotarget       Date:  2016-07-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.